Brief: Eliem Therapeutics Believes Its Cash, Cash Equivalents Of $149.9 Million Are Sufficient To Fund Key Pipeline Catalysts And Operations Until Mid-2024

Climb Bio

18/07/2022 23:06

July 18 (Reuters) - Eliem Therapeutics Inc  ELYM.O :
    * ELIEM THERAPEUTICS INC - BELIEVES ITS CASH, CASH
EQUIVALENTS OF
$149.9 MILLION ARE SUFFICIENT TO FUND KEY PIPELINE CATALYSTS AND
OPERATIONS UNTIL MID-2024
    * ELIEM THERAPEUTICS INC - EXPECTS TO REPORT TOPLINE DATA
FOR ITS
CLINICAL CANDIDATE, ETX-810, IN LUMBOSACRAL RADICULAR PAIN
(LSRP) IN Q3 OF 2022
    * ELIEM THERAPEUTICS INC -  EXPECTS TO BEGIN IND-ENABLING
STUDIES
FOR  ETX-810 IN SECOND HALF OF 2022

Further company coverage:  ELYM.O 

 ((Reuters.Briefs@thomsonreuters.com;))